150 related articles for article (PubMed ID: 37543031)
1. Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors.
Grad RN; Jung S; Ye F; Sun L; Johnson DB; Agarwal R
Oncologist; 2023 Oct; 28(10):911-916. PubMed ID: 37543031
[TBL] [Abstract][Full Text] [Related]
2. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang Y; Liu B; Kotenko S; Li W
Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
[TBL] [Abstract][Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F; Gan G; Li F; Davidoff AJ; Adelson KB; Presley CJ; Adamson BJ; Shaw P; Parikh RB; Mamtani R; Gross CP
JCO Oncol Pract; 2020 Nov; 16(11):e1355-e1370. PubMed ID: 32678688
[TBL] [Abstract][Full Text] [Related]
6. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
[TBL] [Abstract][Full Text] [Related]
7. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life.
Hiramoto S; Taniyama T; Kikuchi A; Hori T; Yoshioka A; Inoue A
Palliat Support Care; 2021 Dec; 19(6):709-714. PubMed ID: 33729120
[TBL] [Abstract][Full Text] [Related]
8. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
Kamminga NCW; van der Veldt AAM; Joosen MCW; de Joode K; Joosse A; Grünhagen DJ; Nijsten TEC; Wakkee M; Lugtenberg M
Br J Dermatol; 2022 Sep; 187(3):381-391. PubMed ID: 35596713
[TBL] [Abstract][Full Text] [Related]
9. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study.
Tawbi H; To TM; Bartley K; Sadetsky N; Burton E; Haydu L; McKenna E
Cancer Med; 2022 Jan; 11(1):139-150. PubMed ID: 34874127
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
[TBL] [Abstract][Full Text] [Related]
14. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Stukalin I; Navani V; Gupta M; Ruan Y; Boyne DJ; O'Sullivan DE; Meyers DE; Goutam S; Sander M; Ewanchuk BW; Brenner DR; Suo A; Cheung WY; Heng DYC; Monzon JG; Cheng T
Oncologist; 2023 Sep; 28(9):812-822. PubMed ID: 37011230
[TBL] [Abstract][Full Text] [Related]
16. New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune-checkpoint inhibitors.
Ab Rahman AS; Strother RM; Paddison J
Asia Pac J Clin Oncol; 2023 Feb; 19(1):179-186. PubMed ID: 35686690
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.
Deng W; Wang Y; Liu X; Liu J; Wang L; Yang Z; Yang M; An Y; Tang C; Sanford NN; Kim BYS; Jiang W
JAMA Netw Open; 2020 Dec; 3(12):e2028627. PubMed ID: 33295975
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study.
Glisch C; Saeidzadeh S; Snyders T; Gilbertson-White S; Hagiwara Y; Lyckholm L
J Palliat Med; 2020 Jul; 23(7):977-979. PubMed ID: 31702481
[No Abstract] [Full Text] [Related]
19. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
20. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]